Literature DB >> 24310228

Serum levels of cytokines in systemic lupus erythematosus : Association study in a Chinese population.

M Zhang1,2, W-D Xu1,2, Y Zhu1,2, P-F Wen1,2, R-X Leng1,2, H-F Pan1,2, D-Q Ye3,4.   

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by abnormal production of autoantibodies and proinflammatory cytokines. The clear pathogenesis of SLE has not been fully elucidated. Cytokine-mediated immunity has been showed to be involved in the pathogenesis of SLE.
OBJECTIVES: The aim of this study was to investigate serum levels of cytokines (IL-19, IL-24, IL-26, IL-31, IL-32, IL-36) in SLE patients, in comparison with normal controls in a Chinese population.
MATERIALS AND METHODS: A total of 65 patients with SLE and 65 healthy volunteers were recruited for the current study. All serum levels of cytokines were measured by enzyme-linked immunosorbent assay (ELISA) kits.
RESULTS: Serum levels of IL-19, IL-24, IL-26, IL-31, IL-32 and IL-36 in SLE patients were not significantly different from the normal controls (all p > 0.05).
CONCLUSION: Serum levels of IL-19, IL-24, IL-26, IL-31, IL-32 and IL-36 in SLE patients were not markedly different from the normal controls. However, functional research should be discussed in future studies to elucidate the roles of these cytokines in SLE.

Entities:  

Keywords:  Autoantibodies; Genetic polymorphism; Interleukins; Lupus nephritis; Synovial membrane

Mesh:

Substances:

Year:  2014        PMID: 24310228     DOI: 10.1007/s00393-013-1274-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  35 in total

1.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

2.  Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade.

Authors:  Bas Heinhuis; Marije I Koenders; Piet L van Riel; Fons A van de Loo; Charles A Dinarello; Mihai G Netea; Wim B van den Berg; Leo A B Joosten
Journal:  Ann Rheum Dis       Date:  2010-12-27       Impact factor: 19.103

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

Authors:  Martin Aringer; Winfried B Graninger; Günter Steiner; Josef S Smolen
Journal:  Arthritis Rheum       Date:  2004-10

5.  Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus.

Authors:  Hye-Young Chun; Jae-Wook Chung; Hyoun-Ah Kim; Jeong-Moon Yun; Ja-Young Jeon; Young-Min Ye; Seung-Hyun Kim; Hae-Sim Park; Chang-Hee Suh
Journal:  J Clin Immunol       Date:  2007-06-21       Impact factor: 8.317

6.  Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.

Authors:  Martin Aringer; Frederic Houssiau; Caroline Gordon; Winfried B Graninger; Reinhard E Voll; Eva Rath; Guenter Steiner; Josef S Smolen
Journal:  Rheumatology (Oxford)       Date:  2009-09-11       Impact factor: 7.580

7.  Dendritic cells activated by IFN-γ/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment.

Authors:  Jutta Horejs-Hoeck; Harald Schwarz; Sebastian Lamprecht; Elisabeth Maier; Stefan Hainzl; Maria Schmittner; Gernot Posselt; Angelika Stoecklinger; Thomas Hawranek; Albert Duschl
Journal:  J Immunol       Date:  2012-04-25       Impact factor: 5.422

8.  IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation.

Authors:  Murielle Corvaisier; Yves Delneste; Henry Jeanvoine; Laurence Preisser; Simon Blanchard; Erwan Garo; Emmanuel Hoppe; Benjamin Barré; Maurice Audran; Béatrice Bouvard; Jean-Paul Saint-André; Pascale Jeannin
Journal:  PLoS Biol       Date:  2012-09-25       Impact factor: 8.029

9.  IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis.

Authors:  Young-Mee Moon; Bo-Young Yoon; Yang-Mi Her; Hye-Joa Oh; Jae-Seon Lee; Kyoung-Woon Kim; Seon-Yeong Lee; Yun-Ju Woo; Kyung-Su Park; Sung-Hwan Park; Ho-Youn Kim; Mi-La Cho
Journal:  Arthritis Res Ther       Date:  2012-11-13       Impact factor: 5.156

10.  Cutting edge: Leptin-induced RORγt expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus.

Authors:  Yiyun Yu; Yaoyang Liu; Fu-Dong Shi; Hejian Zou; Giuseppe Matarese; Antonio La Cava
Journal:  J Immunol       Date:  2013-02-27       Impact factor: 5.422

View more
  10 in total

Review 1.  Interleukin-31: a novel diagnostic marker of allergic diseases.

Authors:  Anja Rabenhorst; Karin Hartmann
Journal:  Curr Allergy Asthma Rep       Date:  2014-04       Impact factor: 4.806

2.  Role of IL-24 in NK cell activation and its clinical implication in systemic lupus erythematosus.

Authors:  Yundi Tang; Xiaotong Sun; Yuxuan Wang; Huijie Luan; Ruijun Zhang; Fanlei Hu; Xiaolin Sun; Xia Li; Jianping Guo
Journal:  Clin Rheumatol       Date:  2021-02-03       Impact factor: 2.980

Review 3.  Role of IL-32 Gamma on Bone Metabolism in Autoimmune Arthritis.

Authors:  Oh Chan Kwon; Soohyun Kim; Seokchan Hong; Chang-Keun Lee; Bin Yoo; Eun-Ju Chang; Yong-Gil Kim
Journal:  Immune Netw       Date:  2018-06-09       Impact factor: 6.303

Review 4.  Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases.

Authors:  Bernhard F Gibbs; Nikolaos Patsinakidis; Ulrike Raap
Journal:  Front Immunol       Date:  2019-06-21       Impact factor: 7.561

5.  Serum Interleukin-26 Is a New Biomarker for Disease Activity Assessment in Systemic Lupus Erythematosus.

Authors:  Benoit Brilland; Maxime Bach-Bunner; Christopher Nunes Gomes; Vincent Larochette; Etienne Foucher; Marc Plaisance; Patrick Saulnier; Nathalie Costedoat-Chalumeau; Pascale Ghillani; Cristina Belizna; Yves Delneste; Jean-François Augusto; Pascale Jeannin
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

Review 6.  A Paradoxical Effect of Interleukin-32 Isoforms on Cancer.

Authors:  Saerok Shim; Siyoung Lee; Yasmin Hisham; Sinae Kim; Tam T Nguyen; Afeisha S Taitt; Jihyeong Hwang; Hyunjhung Jhun; Ho-Young Park; Youngmin Lee; Su Cheong Yeom; Sang-Yeob Kim; Yong-Gil Kim; Soohyun Kim
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

Review 7.  Autoimmune Connective Tissue Diseases-Related Pruritus: Proper Diagnosis and Possible Mechanisms.

Authors:  Lai-San Wong; Yu-Ta Yen
Journal:  Diagnostics (Basel)       Date:  2022-07-21

8.  Association of Plasma IL-32 Levels and Gene Polymorphisms with Systemic Lupus Erythematosus in Chinese Han Population.

Authors:  Yanyun Wang; Bin Zhou; Yi Zhao; Xiuzhang Yu; Yi Liu; Lin Zhang
Journal:  Dis Markers       Date:  2016-02-29       Impact factor: 3.434

Review 9.  Interleukin-24 Immunobiology and Its Roles in Inflammatory Diseases.

Authors:  Yajie Zhong; Xuan Zhang; Waipo Chong
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

10.  Association of BCL2 polymorphisms and the IL19 single nucleotide polymorphism rs2243188 with systemic lupus erythematosus.

Authors:  Weijie Wang; Xinchang Wang; Kepeng Yang; Yongsheng Fan
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.